BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pamvatamig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pamvatamig\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06885840-2050@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Pamvatamig: Phase 2 readout est. (NCT06885840)
DESCRIPTION:Pamvatamig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Stud
 y of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with
  AGA and MET Amplification.\nEstimated primary completion: April 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pamvatamig#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06885840
URL:https://assetmemo.bio/drug/pamvatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04930432-2050@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Pamvatamig: Phase 1/2 readout est. (NCT04930432)
DESCRIPTION:Pamvatamig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: St
 udy of MCLA-129\, a Human Bispecific EGFR and cMet Antibody\, in Patients 
 With Advanced NSCLC and Other Solid Tumors\nEstimated primary completion: 
 30 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pamvat
 amig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04930432
URL:https://assetmemo.bio/drug/pamvatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06015568-2050@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20281104
DTEND;VALUE=DATE:20281105
SUMMARY:Pamvatamig: Phase 1 readout est. (NCT06015568)
DESCRIPTION:Pamvatamig\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Stud
 y of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-
 small Cell Lung Cancer With EGFR Sensitive Mutation\nEstimated primary com
 pletion: 4 November 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pamvatamig#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06015568
URL:https://assetmemo.bio/drug/pamvatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07448116-2050@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Pamvatamig: Phase 1/2 readout est. (NCT07448116)
DESCRIPTION:Pamvatamig\, phase 1/2.\nStudy: Study of MCLA-129 in Combinatio
 n With Ensartinib in Patients With Advanced Solid Tumors.\nEstimated prima
 ry completion: 1 February 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pamvatamig#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07448116
URL:https://assetmemo.bio/drug/pamvatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
